Home › Compare › ACXIF vs ABBV
ACXIF yields 2.30% · ABBV yields 3.06%● Live data
📍 ACXIF pulled ahead of the other in Year 4
Combined, ACXIF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ACXIF + ABBV for your $10,000?
Acciona, S.A., together with its subsidiaries, engages in the energy, infrastructure, and other businesses in Spain and internationally. The company develops, constructs, operates, and maintains wind, solar photovoltaic, solar thermal, hydro, and biomass plants. It also engages in designing, construction, maintenance, and management of infrastructure projects, including bridges, highways, motorways, roads, tunnels, railway, and metros and trams, as well as ports and water channels, airports, freight forwarding, data centers, substations, and transmission lines. In addition, the company offers event planning and management services, as well as designs, constructs, and operates drinking water treatment plants, reverse osmosis desalination plants, wastewater treatment plants, and tertiary treatment plants for water reuse; and constructs, operates, and manages healthcare, universities and campuses, ecosystems restoration, museums and exhibitions, and event planning and management; Further, it provides hotels and holiday resorts, offices, and industrial properties; financial solutions; facility management and airport handling; and museum interior design. It also engages in the fund management, stock broking, real estate, motorbike sharing, and other businesses. Acciona, S.A. was founded in 1916 and is headquartered in Alcobendas, Spain.
Full ACXIF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.